The immune alteration mainly includes, but is not limited to, increased tumor infiltration of CD3+ and CD8+ T cells, reduction of immunosuppressive FoxP3+ regulatory T cells, and an increased ratio of CD8+ T cells/regulatory T cells (CD4+FoxP3+) (a hall mark of clinical efficacy) (Figure 5) [19,30]. The gene discussed is FOXP3; the disease is neoplasm.